Diluted U-500 Humulin Insulin

Phase 1

Diluted U-500 Humulin Insulin is one of 7 therapeutic programs targeting Diabetes Mellitus, Type 1. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetes Mellitus, Type 1Completed

Diabetes Mellitus, Type 1Phase 1

Completed

Competition

Competitive Landscape

10 competitors in Diabetes Mellitus, Type 1

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

2 2

VX-880

Vertex Pharmaceuticals

Phase 3

1 3

Bacillus Calmette-Guérin

Bristol-Myers Squibb

Phase 2

1 4

Insulin Icodec

Novo Nordisk

Phase 3

3 5

Diluted Humalog U-200 Insulin

SStanford University

Phase 1

1 6

Lyumjev U-100 Insulin

SStanford University

Phase 1

1 7

Diluted U-500 Humulin Insulin

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 11 trial

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

Completed·SStanford University·Phase 1·NCT07090824·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Diluted U-500 Humulin Insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Diluted U-500 Humulin Insulin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: SStanford University

Diluted U-500 Humulin Insulin

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Diabetes Mellitus, Type 11 trial

References

Drug Info

Quick Facts

Related News